| Degree of MDM2 Amplification Affects Clinical Outcomes in Dedifferentiated Liposarcoma KLJ Bill, ND Seligson, JL Hays, A Awasthi, B Demoret, CW Stets, ... The oncologist 24 (7), 989-996, 2019 | 32 | 2019 |
| Inhibition of histone deacetylase 2 reduces MDM2 expression and reduces tumor growth in dedifferentiated liposarcoma ND Seligson, CW Stets, BW Demoret, A Awasthi, N Grosenbacher, ... Oncotarget 10 (55), 5671, 2019 | 12 | 2019 |
| Prospective evaluation of the concordance of commercial circulating tumor DNA alterations with tumor-based sequencing across multiple soft tissue sarcoma subtypes B Demoret, J Gregg, DA Liebner, G Tinoco, S Lenobel, JL Chen Cancers 11 (12), 1829, 2019 | 11 | 2019 |
| MDM2-dependent rewiring of metabolomic and lipidomic profiles in dedifferentiated liposarcoma models A Patt, B Demoret, C Stets, KL Bill, P Smith, A Vijay, A Patterson, J Hays, ... Cancers 12 (8), 2157, 2020 | 10 | 2020 |
| Loss of TXNIP enhances peritoneal metastasis and can be abrogated by dual TORC1/2 inhibition D Spaeth-Cook, M Burch, R Belton, B Demoret, N Grosenbacher, J David, ... Oncotarget 9 (86), 35676, 2018 | 4 | 2018 |
| Identification of histone deacetylase 2 (HDAC2) as a novel target for MDM2 directed therapies in dedifferentiated liposarcoma. CW Stets, B Demoret, N Grosenbacher, JL Hays, JL Chen Journal of Clinical Oncology 36 (15_suppl), 11583-11583, 2018 | 2 | 2018 |
| Exploring ceramide metabolism as a potential target in dedifferentiated liposarcoma. B Demoret, A Patt, CW Stets, M Hoang, JL Hays, E Mathe, JL Chen Journal of Clinical Oncology 37 (15_suppl), e22558-e22558, 2019 | | 2019 |
| DEGREE OF MDM2 AMPLIFICATION AFFECTS CLINICAL OUTCOMES IN DEDIFFERENTIATED LIPOSARCOMA. ND Seligson, KLJ Bill, JL Hays, B Demoret, CW Stets, M Duggan, ... CLINICAL PHARMACOLOGY & THERAPEUTICS 105, S38-S38, 2019 | | 2019 |
| Pilot study evaluating the concordance of circulating tumor DNA alterations with tumor-based sequencing in soft tissue sarcoma B Demoret, S Millis, G Tinoco, D Lieber, JL Chen Connective Tissue Oncology Society, 2018 | | 2018 |
| Identifying predictive markers and novel combinations for TORC1/2 inhibition in ovarian and endometrial cancer N Grosenbacher, S Crafton, J David, C Stets, B Demoret, J Chen, J Hays EUROPEAN JOURNAL OF CANCER 103, E132-E132, 2018 | | 2018 |
| Modulation of MDM2 alters the metabolomic programming of dedifferentiated liposarcoma and its sensitivity to cholesterol inhibition B Demoret, A Patt, J Hays, E Mathé, JL Chen Cancer Research 78 (13_Supplement), 3529-3529, 2018 | | 2018 |
| Genomic amplification of CDK4 in dedifferentiated liposarcomas as a predictive biomarker for microtubule disrupting agents. B Demoret, A Rogers, ND Seligson, EA Kautto, JL Hays, JL Chen Journal of Clinical Oncology 36 (15_suppl), 11581-11581, 2018 | | 2018 |
